Ups and downs in prescription drug ranking

Published: 2016-04-22 15:00:05

Updated: 2016-04-22 15:00:05

This first quarter’s ranking of prescription drugs was fluctuated due to patent expirations of original products.

Positions of Baraclude(BMS) and Celebrex(Pfizer) dropped due to their price cuts caused by the last year’s patent expirations. On the other hand, a new hepatitis C treatment, Daklinza named itself in the top 30 even before its 1^st anniversary.

According to the data of UBIST, a p...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.